Rigel Pharma: Fostamatinib Meets Endpoint In Stage 1 Of AIHA Phase 2 Study

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) announced the company recently completed enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its investigational drug fostamatinib for the treatment of patients with warm antibody Autoimmune hemolytic anemia or AIHA. The company said, on a top-line, preliminary basis, the Phase 2 study has achieved the pre-specified primary efficacy endpoint for Stage 1. A response was defined as achieving a hemoglobin level of greater than 10 g/dl and at least a 2 g/dl increase from baseline. The safety profile was consistent with the existing fostamatinib safety database, which comprises over 5,000 patient-years of exposure.

Having met the Stage 1 primary efficacy endpoint, Rigel intends to begin enrollment for Stage 2 of the study in which 20 patients will be enrolled under the same protocol.